Previous close | 58.18 |
Open | 59.14 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 58.37 - 60.36 |
52-week range | 5.68 - 60.36 |
Volume | |
Avg. volume | 111,016 |
Market cap | N/A |
Beta (5Y monthly) | 1.62 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the BofA Securities 2024 Health Care Conference.
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced its financial results and operational highlights for the first quarter ended March 31, 2024.
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, has entered into a co-exclusive licensing agreement with Sanofi (Nasdaq: SNY).